<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565097</url>
  </required_header>
  <id_info>
    <org_study_id>CMO 2007/010;ABR NL16194.091.0</org_study_id>
    <nct_id>NCT00565097</nct_id>
  </id_info>
  <brief_title>Lanreotide as Treatment of Polycystic Livers</brief_title>
  <acronym>LOCKCYST</acronym>
  <official_title>Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of lanreotide in controling total liver volume in patients with
      polycystic livers this study will be performed. A minimum of 38 patients will be recruited
      and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other
      disease states and found to be safe and non-toxic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of total liver volume as determined by CT scan</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of liver volume and individual cyst volume on CT scan.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of kidney volume and individual cyst volume on CT scan</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom evaluation by (validated) questionnaires</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <condition>Hepatomegaly</condition>
  <condition>Liver Diseases</condition>
  <condition>Polycystic Kidney, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanreotide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 yrs-of age

          -  Multiple cysts &gt; 20

          -  Cooperating patient

          -  Is willing and able to comply with the study drug regimen and all other study
             requirements

          -  Willingness to give written informed consent

        Exclusion Criteria:

          -  Use of oral anticonceptives or estrogen suppletion

          -  Females who are pregnant or breast-feeding

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation

          -  History of severe cardiac disease

          -  History or other evidence of severe illness or any other conditions which would make
             the patient, in the opinion of the investigator, unsuitable for the study

          -  Symptomatic gallstones

          -  Renal failure requiring hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost PH Drenth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Medical Center Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loes van Keimpema, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Medical Center Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik Nevens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Gasthuisberg, University of Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2007</study_first_posted>
  <last_update_submitted>February 16, 2009</last_update_submitted>
  <last_update_submitted_qc>February 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2009</last_update_posted>
  <keyword>Polycystic Liver Disease</keyword>
  <keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
  <keyword>Liver cyst</keyword>
  <keyword>Lanreotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
    <mesh_term>Hepatomegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

